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Abstract:  B. anthracis  is a bioweapon of primary importance and its pathogenicity 
depends on its lethal and edema toxins, which belong to the A-B model of bacterial toxins, 
and on its capsule. These toxins are secreted early in the course of the anthrax disease and 
for this reason  antibiotics  must be administered early,  in addition to other limitations. 
Antibodies (Abs) may however neutralize those toxins and target this capsule to improve 
anthrax treatment, and many Abs have been developed in that perspective. These Abs act at 
various steps of the cell intoxication and their mechanisms of action are detailed in the 
present review, presented in correlation with structural and functional data. The potential 
for clinical application is discussed for Abs targeting each step of entry, with four of these 
molecules already advancing to clinical trials. Paradoxically, certain Abs may also enhance 
the lethal toxin activity and this aspect will also be presented. The unique paradigm of Abs 
neutralizing anthrax toxins thus exemplifies how they may act to neutralize A-B toxins 
and, more generally, be active against infectious diseases.  
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1. Introduction 
Anthrax is caused by the gram-negative, spore forming bacterium Bacillus anthracis. This lethal 
disease is still endemic in some parts of the world, primarily to herbivores in the less-developed 
countries but can affect a wide range of species, including humans. Anthrax is considered a biological 
threat due to the historical weaponization of this agent since World War II, in addition to recent events, 
particularly the intentional anthrax letter attacks in 2001 in the United States. B. anthracis is classified 
by the Centers for Disease Control and Prevention (CDC) as a category A select agent, representing 
the biological agents most at risk of being weaponized [1]. B. anthracis pathogenesis depends on three 
virulence factors, the production of a protective capsule [2] and of two A-B toxins [3]. The A-B (or 
“binary”) bacterial toxins consist of a two component complex whose “B” subunit is responsible for 
cell surface binding,  and the “A” subunit  which  is responsible for the enzymatic activity of  the  
toxin  [4].  The anthrax  toxins are  composed  of  three different proteins,  a single receptor-binding  
B-subunit, designated as protective antigen (PA), and two alternative A-subunits, the lethal factor (LF) 
and the edema factor (EF). LF interacts with PA to form the lethal toxin (LT) and EF interacts with PA 
to form the edema toxin (ET) [5]. 
The crystal structure of PA83 has been resolved [6] (Figure 1) and shows four different domains, 
each playing a different role in the intoxication mechanism (residues in this review are designated 
according to their numbering in three-dimensional structures). Domain I (residues 1–258) contains the 
furin proteolysis site [6], and the LF/EF binding site. Domain II (residues 259–487) is involved in 
heptamer and pore formation, and interacts with anthrax toxin receptors (ATRs) [9,10]. Domain III 
(residues 488–595) is also involved in heptamer formation [11]. Domain IV (residues 596–735) is 
essential in the recognition and binding to the cellular ATRs [12,13].  
Figure 1. Structures of protective antigen (PA), lethal factor (LF) and edema factor (EF) 
subunits. PA structure has been obtained using file 1acc from the Protein Data Bank [6]. 
LF and EF structures are derived from the files 1j7n [7] and 1xfv [8], respectively. For 
each subunit, the different domains are identified on ribbon models and their respective 
function is indicated. The color  code utilized on ribbon models was re-utilized for 
schematic rendering.  
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Toxin entry into host cells involves several steps. First, PA in the form of an 83-kDa protein (PA83) 
binds to ATRs, the tumor endothelial marker 8 (TEM-8) and the capillary morphogenesis protein-2 
(CMG-2) [14,15]. PA83 amino-terminal 20-kDa region (PA20, residues 1–167) is then proteolytically 
cleaved by a furin-like protease and released (Figure 2). The PA63 fragment remains bound on cell 
surface and forms a homo-heptameric structure that binds EF or LF, and promotes their cell entry by a 
clathrin-dependant endocytosis.  LF is a zinc-dependent protease specific for the mitogen-activated 
protein kinase kinase family [16,17] and EF is a calmodulin-activated adenylyl cyclase [8,18]. 
Figure 2. The different steps of anthrax toxins entry, and their inhibition by antibodies. 
(A) Various steps of anthrax toxins entry. PA83 binds to its cell receptors and is processed 
by furin on the cell surface. PA20 is released and PA63 remains attached to the receptor. 
Heptamerization of PA63 induces the formation of LF/EF binding site. The toxin complex 
is then endocytosed. (B) Inhibition of the various steps of anthrax toxins entry by Abs. 
Neutralizing Abs act at each entry step: binding of PA83 to its receptors (1), PA83 cleavage 
by furin (2), PA20 release (3), PA63 heptamerization (4), LF/EF binding to the heptamer by 
targeting PA (5) or LF/EF (6), and endocytosis of the toxin (7). 
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The crystallographic structure of LF has also been resolved (Figure 1) [7]. LF is composed of four 
different domains.  Domain I (LFN;  residues 1–254)  interacts  with PA  [19].  Domain II (residues   
263–297 and 385–550) presents a pocket which captures its proteolysis substrate. Domain III (residues 
303–382),  inserted  within domain II, plays a role in the enzymatic specificity [7,20]. Domain IV 
(residues 552–776) contains the catalytic center (HExxH), where the first H is localized at position 
686, E is localized at 735 and the last H is at position 690. 
The EF structure was the last to be resolved (Figure 1) [8] and it presents two functional domains, 
domain I (EFN, residues 1–291) and domain II (residues 292–798). EFN interacts with PA in the same 
way as the LFN. Domain  II  is responsible for the adenylate cyclase activity of EF, leading to an 
uncontrolled increase in intracellular cAMP concentration in host cells [8,18].  
Antibodies (Abs) against anthrax have historically demonstrated therapeutic potential and, in their 
recombinant form, represent several products currently advancing into clinical trials. Indeed, the first 
specific treatment of anthrax, Achille Sclavo’s serum, consisted of polyclonal antibodies. This bovine 
derived product, used in the 1890’s, increased survival rates of cutaneous anthrax from 75 to 96% [21]. 
Antibiotics have now replaced the Abs  as main molecules for anthrax treatment but they have 
limitations which, in turn, may be compensated by Abs. In effect, current antimicrobials (fluoroquinolone, 
tetracycline or penicillin G) [22,23] require early administration in order to provide protection, due to 
the rapid course of infection and toxins secretion after exposure to B.  anthracis  spores by the 
pulmonary route. Additionally, this treatment must be continued for 60 days. Following the 2001 
anthrax letter attacks, the compliance for this treatment was only about 40% [24,25]. Abs targeting 
anthrax toxins could be used to reduce this lengthy treatment time.  The  natural  emergence  of 
antimicrobial resistant strains  [26,27], as well as resistant strains of anthrax  obtained  in vitro, 
demonstrates the need for alternate treatments [28,30]. Consequently, Abs are generally expected to 
increase the therapeutic window, decrease the length of treatment, and overcome potential antibiotic 
resistant strains. Abs enabling these functions, by targeting the pathogenic mechanisms at various steps 
involving LT/ET toxicity, will be reviewed in this article. The current field of Abs against anthrax 
includes multiple anti-PA Abs under clinical testing as well as several anti-LF, anti-EF, and anti-capsule 
Abs. Additionally the paradoxical role of Abs, enhancing toxicity, will be briefly discussed. Of note, 
the scope of the manuscript is not to correlate Abs and vaccination, but rather how monoclonal and 
recombinant Abs act. 
2. Antibodies Neutralizing the Anthrax Toxins  
PA has been regarded as the most important target of neutralizing Abs because (i) it plays a central 
role for the formation of both LT and ET, (ii) it is involved at the earliest stages of the intoxication 
process, and (iii) vaccines composed of PA showed that PA-binding Abs effectively limit B. anthracis 
pathogenicity. Several anti-PA monoclonal antibodies (mAbs) have been isolated and in certain cases, 
their neutralization mechanisms were studied. Interestingly, neutralizing Abs directed against the four 
domains of PA were described, and neutralized at each step involving this subunit: PA interaction with 
ATRs, PA proteolysis by furin  and the release of PA20, PA heptamerization, PA interaction with 
LF/EF, and the endocytosis of the toxin complex (Figure 2). As an alternative to anti-PA, Abs against 
LF and EF have been considered. These Abs act at the latest stages of the toxin entry: the interaction of Toxins 2011, 3                                       
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LF/EF with the heptamer and the endocytosis of LT/ET. The protective efficacy of anti-LF Abs has 
been shown in in vivo models of the disease, often with a better efficacy than anti-PA [31]. 
2.1. Antibodies Inhibiting PA/Receptors Interaction 
The first anthrax toxin entry step involves the high affinity (KD = 170 pM) binding of PA to one of 
the two known ATRs [32] (Figure 2). Only the extracellular domain of these receptors, related to the 
von Willebrand factor A (vWFA) domain [33], is involved in the anthrax toxin entry. The vWFA 
domains share 60% of their amino acids, and include a metal ion-dependent adhesion site (MIDAS) 
motif which is most likely involved in their interaction with PA. Mutagenesis studies have shown that 
the carboxylate group of aspartate, at position 683 on PA, plays a critical role in the PA-receptors 
interaction by completing the coordination of MIDAS [34]. The X-ray crystal structure of PA 
complexed with the vWFA domain of CMG2 has been resolved and identified the four PA loops that 
are essential for ATRs binding: the loop between residues 340–348 (domain II), between residues  
654–662, 681–688, and 714–716 (domain IV) [9]. 
The first mAbs, whose neutralization properties  were  tested  in vitro  and  in  vivo,  inhibited  the 
interaction between PA and the vWFA domains of the ATRs. In particular, 14B7, an Ab with a high 
affinity (KD = 0.33 nM), neutralized LT and ET by blocking PA interaction with cells [35]. In a study 
of 36 anti-PA mAbs, only two were neutralizing: 3B6 and 14B7. Competitive binding experiments 
have shown that 3B6 and 14B7 recognized the same epitope on PA. Utilizing a mutagenesis strategy, 
the precise epitope of 14B7 was identified as residues 682, 684, 685, 686, 687 and 688 [13] (see 
sequence alignment on Figure 3). This neutralizing epitope corresponded to one of the four important 
loops on PA, involved in its interaction with ATRs, thus explaining the high efficiently of 14B7. This 
loop was additionally targeted by other neutralizing Abs such as 35PA83, a macaque-derived Ab of 
high affinity (KD = 3.4 nM) which neutralized LT in vitro (IC50 = 5.6 nM) [36], and whose epitope 
have been localized between residues 686 and 694 by Pepscan analysis. With the same technology, 
murine mAbs 1-F1 and 2-B12 epitopes were precisely localized between residues 692–703 and 716–727 
respectively, two regions that are immediately adjacent to the 14B7 binding site [37]. The epitope of 
two chimpanzee Abs, W1 and W2, which prevented the binding of PA to RAW265.7 cells, were localized 
between residues 614–735 and this region encompassed three of the four PA loops involved in the 
ATRs interactions [38]. Identically, Mab 7.5 bound to PA domain IV between residues 608 and 735 [39]. 
Several anti-PA Abs, directed against domain IV of PA, act by inhibiting PA interaction with its cell 
receptors but their epitopes were not precisely mapped [31,40–42]. These Abs include Raxibacumab, a 
human IgG1, also designated Abthrax
TM, isolated using phage display technology [43]. Toxins 2011, 3                                       
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Figure 3. Neutralizing epitopes inhibiting PA-ATRs interactions compared with anthrax 
toxin receptors (ATRs) binding site. (A) Three-dimensional localization of the neutralizing 
epitopes on PA. PA structure has been obtained using file 1acc from the Protein Data  
Bank [6] and was colored in grey. Residues of the four PA loops constituting the ATRs 
binding site,  residues 340–348  (part of  domain II), residues 654–662, 681–688, and   
714–716 (part of domain IV) were colored in red. The core of the four well-defined PA 
neutralizing epitopes were delimited in blue for 14B7, in green for 35PA83, in purple for  
1-F1 and in yellow for 2-B12. After Ab binding to the core epitope, the interface between 
Ab and PA should cover a larger surface. (B) Localization of the neutralizing epitopes on 
PA sequence. Localization of the four epitopes was given as sequence alignments; residues 
constituting ATRs binding site were colored in red on PA sequence. 
(A) 
 
(B) 
               654                                                                        729 
                |                           (Domain IV)                                    | 
PA              EVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSK 
14B7 epitope:   ----------------------------N-KLPLY----------------------------------------- 
35PA83 epitope: --------------------------------PLYISNPNY----------------------------------- 
1-F1 epitope:   --------------------------------------PNYKVNVYAVTK-------------------------- 
2-B12 epitope:  --------------------------------------------------------------TSTNGIKKILIFS- Toxins 2011, 3                                       
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Among  the Abs presented above, two have entered clinical trials for therapeutic approval, 
Raxibacumab and Anthim
®, derived from 14B7.  Raxibacumab  was shown to  be  protective  both 
prophylacticly and therapeutically in a non-human primate (NHP) model using a 40 mg/kg intravenous 
(i.v.) dose, eliciting respective protections of 90% (100 LD50) and 64% (200 LD50) against aerosolized 
Ames spores. Tolerance data was evaluated in a group of human volunteers [44] and a total of 65,000 
doses of Raxibacumab has been ordered for the US Strategic Stockpile while this mAb awaits final 
FDA approval [41]. Anthim
® (Elusys, Pine Brook, NJ), previously ETI-204, was developed from the 
murine mAb 14B7 as a chimeric deimmunized mAb utilizing the DeImmunisation
® process (Antitope, 
Cambridge, UK) [45]. In vivo analysis utilizing the rabbit Ames spore inhalation model demonstrated 
complete prophylactic (163 LD50) and 80% therapeutic (172 LD50) protection when ~4 mg/kg of 
Anthim
®  was administered by i.v. Although the results have not been published, Anthim
®  has 
completed Phase I clinical trials both alone and in combination with antibiotics under National Clinical 
Trials (NTC) study designations NCT00829582 and NCT00138411. 
2.2. Antibodies Inhibiting PA Cleavage by Furin 
After PA83 has bound ATRs, it is cleaved by a cell membrane-associated furin into two proteins, a 
63 kDa (PA63) and a 20 kDa (PA20) fragment, with PA63 remaining bound to the receptor [46]. This 
cleavage occurs at R167, part of the RKKR cleavage site (residues 164–167), which is localized in an 
exposed loop of the domain I [6]. This cleavage is necessary to expose a large hydrophobic surface on 
PA63 which binds either LF or EF [47,48].  
Murine mAb 48.3 [39] is an Ab protective in vivo against B. anthracis, which was shown to block 
this enzymatic cleavage in an assay where PA83 and mAb 48.3 were incubated on CHO-K1 cells. The 
authors report that, when the concentration of mAb 48.3 increased, the abundance of PA63 decreased 
thus showing inhibition of PA83 cleavage. The epitope of mAb 48.3 was localized between residues 
314–608, according to the reactivity of mAb 48.3 with various PA fragments. This epitope was then 
precisely mapped by screening a library of phage-displayed peptides, as located in the PA domain II 
between residues 412–419 thus away from the cleavage site. The authors concluded that the steric 
hindrance of mAb 48.3, or mAb 48.3-induced conformational changes, prevented PA83 cleavage. MAb 
7.5G, another murine mAb, inhibited the toxicity of anthrax lethal toxin in vitro and in vivo [49]. In an 
assay where PA83 and furin were incubated for various periods of time in the presence or absence of 
mAb 7.5G, it was observed that there were less PA63 and PA20, and more PA83, in the presence of mAb 
7.5G than in its absence. It was similarly concluded that mAb 7.5G inhibited PA83 cleavage by furin. 
In an ELISA, mAb 7.5G bound to the first 157 amino acids of PA83 domain I, and thus mAb 7.5G 
epitope was mapped in the domain encompassing the cleavage site, well in agreement with its 
mechanism of action. Of note, 22G12, a potent inhibitor of anthrax LT in vitro and in vivo, bound PA83 
near the cleavage site, as its binding was inhibited by trypsin [50] and it prevented subsequent steps 
necessary for toxicity. Unexpectedly, 22G12 did not prevent cleavage but was thought to inhibit the 
release of PA20, by “clipping” PA63 and PA20. 
Only mAbs 7.5G and 48.3 have been positively  tested  in vivo,  utilizing  two  murine  models, 
intoxication with LT and subcutaneous infection with spores. Of note, the use of 48.3, in combination 
with mAbs 50.8 and 7.5, constituted  the first oligoclonal set of mAbs that provided  synergistic Toxins 2011, 3                                       
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protection against anthrax [39]. Although a single therapeutic would be less expensive to develop, an 
oligoclonal mixture of mAbs may be necessary for neutralization and may also act synergistically with 
other antimicrobials.  
2.3. Antibodies Inhibiting PA Heptamerization 
PA63  molecules, bound to their cellular receptors and separated from PA20,  diffuse in the   
two dimensions of the membrane and form spontaneously heptameric complexes, which are 
thermodynamically favorable over the monomeric form. Mutations in the loop encompassing residues 
510–518 of the PA  domain  III, and more particularly the residue 512,  strongly inhibited  this 
oligomerization, driving to the inhibition of the LT toxicity. These results indicated that the PA domain 
III was particularly involved in PA heptamerization [11,51].  
Murine mAbs 2D3, 2D5 and 10D2 neutralized LT in vitro, binding to the region located between 
residues 581–601. Their mechanism of action was initially hypothesized to be either inhibition of PA 
binding to ATRs or inhibition of PA heptamerization, but the latter may be regarded as the most 
probable due to their epitope location [52]. The human mAb  AVP-21D9 strongly neutralized  
B. anthracis and bound to PA47, a PA fragment corresponding to a portion of domain III, and to 
domain IV [53]. This mAb was shown to inhibit heptamer formation in vitro, possibly by masking the 
assembly interfaces [50]. A strongly protective mAb, MDX-1303, bound PA83 but it did not prevent 
PA83 interaction with ATRs. More precisely, it was shown to bind PA63, but it did not inhibit LF 
binding  [54].  The  MDX-1303 epitope has been  located in PA47, as with  AVP-21D9. From these 
elements, it was concluded that MDX-1303 inhibited heptamer assembly or function, and it was shown 
that the absence of MDX-1303 Fc region decreased its activity by a ten fold. It was thus inferred that 
the bridging of PA with Fc receptors (FcRs) was involved in the neutralization mechanism, which 
might depend on the inhibition of heptamer assembly or function. Of note, it was shown that the 
neutralizing activity of sera raised against PA also depended on Fc receptors, in an experiment where 
the blockade of FcRs with mAbs reduced neutralization. Thus, MDX-1303 may depend on an activity 
also present in sera raised by the anthrax vaccine. A third mAb, murine 1G3 mAb, reacted with PA63 
exclusively in its heptameric form and its epitope has been located between residues 168–314, on 
domains I and II [52]. By electron microscopy, it was shown that 1G3 binding to heptamers may stitch 
two heptamers together, resulting in dodecamer-like supercomplexes [55] that prevented following 
steps from occurring. 
Two  Ab  therapeutic candidates,  able to neutralize PA heptamerization,  are undergoing clinical 
trials. Valortim
® (PharmAthene Inc, Annapolis, MD), or MDX-1303, is currently in Phase I clinical 
trials [54]. NHPs exposed to 200 LD50 aerosolized Ames spores demonstrated complete survival after 
the administration of 1 mg/kg of this Ab, at 1-h post-exposure. Although Phase I studies of Valortim
® 
were either suspended or terminated due to an adverse event, ongoing investigations are underway to 
determine the cause of this reaction and this mAb remains in Phase I trials under study designations 
NCT00964834 and NCT00964561. A second human anti-PA IgG1, Thravixa
TM (previously AVP-21D9), 
has been produced by Emergent (Rockville, MD) and is currently in Phase I clinical trials under the 
study designation NCT01202694. Utilizing rabbit models, subcutaneous administration of Thravixa
TM 
(2 mg/kg) provided complete protection against 102 LD50  aerosolized Ames spores when given Toxins 2011, 3                                       
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concurrently,  and 66% protection at 24-h  post challenge. Additionally, a synergistic effect was 
observed using combined treatments of Thravixa
TM with ciprofloxacin in a murine model. Although 
not yet assessed for tolerance, the potential for in vivo synergistic effects with antibiotics and the 
existence of two human mAbs in clinical trials highlight inhibition of PA heptamerization  as a 
promising mechanism of protection against anthrax.  
2.4. Antibodies Inhibiting PA-LF/EF Interactions 
After heptamer formation on the host cell surface, three LF and/or  EF  proteins  bind to PA63 
competitively and with high affinity (KD = 1 nM) [56] by their N-terminal domains (LFN and EFN) also 
called PA-binding domains  (260 first residues) [6,51,57,58]. LF/EF residues involved in the PA 
binding site were localized by mutagenesis studies [59,63] and by the analysis of a LF-PA co-crystal 
structure [57]. Two regions of LF are involved in that binding. The first region is the first alpha helix 
(LFα1 helix), located between residues 29–50, which dock into a deep amphipathic cleft on the surface 
of the PA63 heptamer. The second region is composed of LFN hydrophobic residues of the alpha helix 
10 (LFα10 helix), residues L188, Y223, H229, V232, L235 and Y236, which are closely involved in 
an interaction with a hydrophobic region on PA, involving PA residues F202, P205, I207 and I210. 
By screening a naïve phage-displayed library against cell-bound PA63, three human single-chain 
variable fragments (scFvs) that possess neutralizing activity against anthrax toxin have been isolated 
and converted into Fabs, SS87, SS70 and SS73. Of these three Fabs, SS87 provided the best in vitro 
neutralization when added after PA heptamerization on the cell surface, and before the addition of  
LF [64]. Consequently, SS87 could not act by inhibition of PA cleavage nor heptamerization, but  
by inhibition of a later step which could  only be the interaction between  PA and EF/LF. By 
immunofluorescent microscopy  experiments it was shown that SS87 recognized and bound  to the 
heptamer and consequently competed with the LF/EF interaction, which was thus directly identified as 
the inhibition mechanism.  Unfortunately,  the  SS87  epitope  was  not  mapped.  This mechanism of 
neutralization is certainly shared by the human Fab A8 [40]. This Fab was isolated from a phage 
displayed human scFv library and protected RAW264.7 macrophage cells against an LT challenge, 
similar to the cell assay described above, but no direct proof of the neutralization mechanism was given. 
Apart from these anti-PA Abs, the interaction between PA and LF/EF can also be inhibited by Abs 
targeting LF and EF. This was first confirmed by studies using a DNA vaccine encoding LF, which 
established in vivo the protective efficacy of anti-LF Abs [65]. In 2003, the murine mAb LF8 was 
shown to neutralize LT in vitro, and to protect in vivo utilizing a murine model of the disease [66]. 
Using an electro-mobility shifting assay (EMSA), it was shown that mAb LF8 inhibited LF binding to 
PA, forming stable LF8-LF complexes instead of PA-LF complexes. The LF8 epitope was recently 
localized by a standard solid-phase peptide assay in the LF domain III, between residues 314–323, thus 
not in the region known to be involved in the PA-LF interaction [67]. Domain III is known to be 
involved in LF enzymatic activity but not in PA binding, thus this mapping was not predicted. The 
neutralizing mAb 10G3 possessed the same neutralization mechanism as LF8 and its epitope was 
mapped between residues 350–361, close to the LF8 epitope, using the same peptide assay [67,68]. 
This epitope was also targeted by the neutralizing mAbs 5B13B1 and 3C16C3, whose mechanism of 
action remained undetermined but should be identical, based on epitope mapping [69]. Domain III is Toxins 2011, 3                                       
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located at the opposite face on LF with regard to the PA binding site (LFN) and thus the binding of 
these Abs may not inhibit the PA/LF interaction  by steric hindrance, but rather by altering  the 
conformation of LF. A highly neutralizing anti-LF scFv, 2LF, has been isolated from a  
phage-displayed library, built from an immunized NHP. 2LF inhibited the toxin complex formation as 
described for LF8 [70] and was shown to cross-react with EF. After epitope mapping with peptides 
failed, alanine shaving and scanning indicated that the 2LF epitope was localized in the LFα10 helix 
region of LFN, directly consistent with its neutralization mechanism (submitted manuscript). A human 
anti-LF IgG1, IQNLF, neutralized LT in vitro with an efficacy three-fold higher than the anti-PA mAb 
IQNPA. It conferred passive protection in A/J mice infected by the B. anthracis Sterne spores [31]. 
The IQNLF epitope was localized within the LFN domain using isolated LF domains and western blot 
analysis, but it was not more precisely mapped. Nevertheless, the authors expected that it may block 
the LT formation by disrupting or preventing the interaction of LF with the PA heptamer. Recently, the 
mAb H10 has been isolated from a mouse immunized with LFN domain [71]. As with 2LF, this mAb 
cross-reacted with LF and EF, due to similarities between LFN and EFN, and neutralized both toxins  
in vivo. Regarding anti-EF Abs, the mAb 9F5 inhibited the binding of radiolabeled EF to cell-bound 
PA [72]. Three EF fragments were obtained by acid hydrolysis with molecular weights of 18 kDa  
(N-terminal, residues 1–156), 53 kDa (central) and 17 kDa (C-terminal). It was shown by immunoblot 
that 9F5 bound specifically the N-terminal fragment, and it was thus expected that 9F5 inhibited the 
binding of EF to the PA63 heptamer by targeting this first half of EFN, but its epitope was not more 
precisely mapped.  
Although no mAbs inhibiting  the interaction  of PA-LF/EF have  entered clinical trials,  the 
development of human mAbs such as IQNLF, SS87, Fab A8, 2LF as well as the cross-reactivity of 
mAb H10 demonstrated the therapeutic potential of this mechanism. Of these Abs, only IQNLF and 
2LF have been tested in vivo utilizing murine and rat models of intoxication. Future aerosol testing 
utilizing rabbit and/or NHP models will help determine if Abs inhibiting PA-LF/EF interactions will 
have clinical applications. 
2.5. Antibodies Inhibiting Endocytosis and Translocation 
The formation of the PA63  heptamer stimulates the endocytosis of PA-LF/EF complexes  [73]. 
Under the acidic conditions of the endosomes, the heptamer is driven to membrane insertion and forms 
a pore, protecting the toxins from lysosomal proteases and facilitating EF and LF translocation into the 
cytoplasm [74].  
Two chimeric chimpanzee/human mAbs, LF10E and LF11H, bound to LFN (known to be involved 
in the interaction with PA) but it was shown by western blot analysis that these mAbs did not inhibit 
the association of LF to activated PA [75]. In vitro studies demonstrated that these mAbs did not 
prevent  LT  formation; however,  both of these mAbs  inhibited the LF-driven  cleavage of  
mitogen-activate protein kinase in the cytosol. The authors have hypothesized that, because LF10E and 
LF11H did not bind the enzymatic site, they inhibited the LF translocation. In addition to the inhibition 
of LF by this mechanism, the chimeric chimpanzee/human mAb EF13D, which bound to domain IV of 
EF, was shown to inhibit EF activity through the inhibition of EF binding with calmodulin (CaM) [76]. 
In vitro measurements utilizing migration under native conditions and analytical ultracentrifugation Toxins 2011, 3                                       
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(AUC)  showed that  EF13D binding to EF displaced  CaM bound to  EF.  In effect, utilizing both 
methods, incubation of the three proteins (EF, CaM and Fab EF13D) always resulted in a mixture of 
EF-Fab EF13D complexes plus free CaM. Further AUC testing utilizing CaM-EF complexes mixed 
with free Fab EF13D resulted in a shift to EF-Fab complexes plus free CaM. However, the authors of 
this study did not expected the Fab EF13D to enter the CaM rich cytoplasm, thus they suggested that 
the mAb EF13D protected by another mechanism. This mechanism would be the blocking of EF 
endocytosis or translocation through the PA heptamer pore. Although this hypothesis has yet to be 
confirmed, additional mechanisms may also be at play according to these authors.  
Chimpanzee/human chimeric mAbs should be well tolerated for human use, given similarities 
between both species. In vivo analysis has only been performed in murine and rat models, utilizing 
intravenous and footpad intoxication models [76]. Meeting the FDA animal rule would require the 
efficacy of these mAbs to be demonstrated in rabbits or NHPs challenged by aerosolized spores. 
Nevertheless, these humanized mAbs constitute  the closest therapeutic products utilizing  this 
neutralization mechanism. 
3. Antibodies Directed Against Bacillus anthracis Capsule 
B. anthracis virulence factors are not only its toxins, but also consist of a poly-γ-D-glutamic acid 
(γDPGA) anti-phagocytic capsule,  encoded on the pXO2 plasmid.  This capsule is essential for   
in vivo distribution of the bacteria from the lungs [77,78]. Although previously described as poorly 
immunogenic [79], the γDPGA capsule has recently become a target for the generation of both vaccine 
and therapeutic Ab candidates.  
The murine IgG3, mAb F26G3, was developed by immunizing mice against γDPGA [80]. When 
injected, this mAb elicited 90% protection in a  murine  pulmonary  challenge model. Kozel et al. 
developed several additional murine mAbs against γDPGA, which bound to separate areas of the 
capsular architecture, suggesting a certain level of complexity in the structure of the capsule [81].  
Chen  et al.  developed two chimeric chimpanzee/human mAbs, 11D and 4C, from chimpanzees 
immunized against γDPGA. The variable regions of 11D and 4C were fused to Fc portions of either γ1 
or γ3 isotype [82]. The authors observed similar binding affinities with IgG1 and IgG3 versions of 
these Abs, but increased protection utilizing the IgG1 isotype. In vivo testing against an intratracheal 
Ames spore challenge (1,5.10
4 spores, i.e., 15 LD50) in a murine model elicited complete protection 
with a 1 mg injection given at 18-hrs pre-challenge, or as late as 20-h post-challenge, utilizing the 
IgG1 isotype.  
The protection elicited by 11D and 4C against an intratracheal challenge of Ames spores in murine 
models emphasized  the advancing therapeutic  development of mAbs utilizing  this  mechanism  of 
protection. However, further testing utilizing rabbit and/or NHP animal models, which would fulfil the 
FDA animal rule, will ultimately demonstrate if these mAbs will have the protective capacity for 
further clinical development.  Toxins 2011, 3                                       
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4. The Particular Case of Antibody Enhancing Toxin Activity 
Antibodies can paradoxically increase the cytotoxic effects of LT. Previously, antibody-dependent 
enhancement (ADE) of pathogenicity was only shown with mAbs developed against viruses [83]. 
Regarding anthrax, Mohamed et al. demonstrated the enhancement of LT cytotoxicity with a panel of 
mAbs directed against PA [84]. In vitro studies showed that these enhancing mAbs interacted with 
murine macrophage Fcγ receptors, and were hypothesized to stabilize PA on the cell surface, thus 
increasing the quantity of PA internalized by macrophages [84]. Recently, ADE by mAbs directed 
against PA was further demonstrated in vivo [85]. In vitro analysis of 17 enhancing mAbs yielded eight 
separate antigenic regions on PA. Of note, utilizing sub-lethal LT concentrations in vivo, Little et al. 
was able to induce a lethal response in Fisher rats utilizing four mAbs separately. The authors of this 
second study remarked that the Fcγ receptor-dependent mechanism of enhancement may not be the 
only one responsible for the increased LT pathogenicity.  
These results could imply that immunization with PA may elicit a response that would include such 
enhancing Abs, but the existence of this response should be further studied. The existence of these 
enhancing mAbs could explain why PA-derived vaccines are not always completely protective. This 
suggests the need for caution when developing Abs directed against a single antigen of anthrax for 
clinical purposes, and Abs neutralizing alternative antigens (e.g., LF and EF) might be needed.  
5. Discussion and Conclusion 
B. anthracis is one of the biological agents most at risk of being weaponized, and it was the subject 
of ongoing fundamental studies even before the intentional dissemination of spores in the US, in  
2001  [1]. This very sad event led to several observations, including the fact that the therapeutic 
window was too narrow for optimal therapy [24]. Recombinant Abs against anthrax were then actively 
developed because Abs of animal origin had previously been shown to increase that window, in animal 
models of the disease, and also shortened the duration of antibiotherapy. Those animal Abs were 
directed against anthrax toxins, which were also targeted by recombinant Abs, isolated at a time when 
the structures of these toxins have been resolved.  The study  of these new  Abs has  increased the 
knowledge of anthrax toxins neutralization, which now may be regarded as a model. It shows the 
variety of mechanisms which may be inhibited for toxin neutralization: protein-protein interactions, 
cleavage, heptamerization, endocytosis and translocation. Of note, the existence of certain mechanisms 
has been directly proven in vitro, such as the inhibition of interaction by EMSA experiments [66,86], 
while other mechanisms were hypothesized only, as a consequence of the exclusion of others. Indeed, 
one may be cautious with hypothesized mechanisms, particularly if others have been demonstrated and 
in fact resemble mechanisms recently observed elsewhere, such as neutralization of botulinum toxin 
proteolytic activity [87]. The inhibition of endocytosis and translocation mentioned above may thus 
benefit from further  studies. Regarding the  better established mechanisms  of neutralization, it is 
striking that the two main Abs characteristics described long ago as essential, affinity and specificity, 
are indeed key. Affinity is essential because the Abs compete with a natural ligand—whether receptor, 
substrate, another sub-unit—to inhibit interaction, cleavage, heptamerization respectively. Nanomolar 
affinities are often requested for such an efficient competition. This competition also explains that Ab Toxins 2011, 3                                       
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concentration plays a role in toxin neutralization, as it relies on a dynamic equilibrium. Specificity is 
the second key Abs characteristic because, in most studies, highly neutralizing Abs are shown to target 
exactly the region involved in the inhibited process (see Figure 3) [35–38]. However, certain studies 
have presented epitopes which were not located in the regions known to be involved in the inhibited 
process [66,67], and steric hindrance or alteration of the antigen conformation may in effect explain 
these results. In certain studies however, the epitopes have been localized with peptides, and it is the 
experience of the authors of the present review that such studies might give misleading results if they 
are not rigorously interpreted. In particular, the peptide thought to represent the epitope should be 
demonstrated as efficiently competing with the natural ligand for Ab binding. In the absence of such 
competing effect, an epitope mapping was re-performed by alanine scanning and results found to be 
completely different from those obtained with peptides (manuscript in preparation). If specificity is 
generally a favorable characteristic, allowing high efficiency and good tolerance, it may also represent 
Abs Achille’s heel because a single mutation might abolish the binding of a specific Ab if localized in 
its epitope. While such a mutation is difficult to envision in epitopic regions essential for protein 
function, this risk can be limited by the development of oligoclonal Abs [13,88]. Recombinant Abs 
against anthrax did not always neutralize toxins, but also targeted spores. In that case, the activation of 
immune effectors became key, as shown by isotype importance and the role of affinity and specificity 
was then certainly far less important than it was for toxins neutralization.  
The fact that Abs may enhance pathogenesis is very well exemplified in the paradigm of anthrax, 
and should be kept in mind when Abs target a pathogen whose host cells bear FcRs [84]. In that case in 
effect, IgGs interacting with the pathogen may bind to the FcRs and bring the pathogen closer to its 
host. If the pathogen is not neutralized, this Fc-FcRs binding is likely to increase pathogenicity. When 
developing Abs for therapeutic or prophylactic purposes, ADE risk may be reduced by changing Fc 
isotype to reduce FcRs binding, or even suppressed by replacing the Fc portion by another molecule 
increasing Ab  fragments  half-life,  such as PEG. This  risk  is  far more difficult to limit  when  
developing vaccines. 
The paradigm of anthrax demonstates that, particularly if infective pathogenesis is elucidated, such 
as with the central role of toxins in anthrax, Abs may be remarkable anti-infective new molecules. 
Such new molecules are in high demand at present, due to mounting antibioresistance [26,27]. The 
historical anti-infective Abs should be actively developed for prophylactic or therapeutic purposes as 
they were against anthrax, but in their recombinant form.  
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